Taylor Fritz blames opponent for Wimbledon curfew controversy after match suspended A trucker in his late 70s who can't ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Innovation in obesity treatments, Alzheimer's detection and medical-device applications is setting the stage for a number of ...

Nearly two-thirds of patients who started on weight-loss drugs Wegovy or Zepbound last year were still taking them a year ...

Novo Nordisk executives overlooked warnings ahead of Wegovy's launch, leading to supply issues, high costs, and challenges competing with Eli Lilly's Zepbound.

COPENHAGEN (Reuters) -Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared ...

The effect of Novo Nordisk’s amycretin injections on body weight showed no signs of plateauing after 36 weeks, suggesting the ...

Novo Nordisk’s next-gen weight loss drug and Zepbound “seem fairly equal to me,” one expert says after release of new ...

A separate Prime analysis, however, of year-over-year claims data for Wegovy and Zepbound only found an improvement in ...

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...